Overview

Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation

Status:
Active, not recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open label, randomised phase II clinical trial for patients with metastatic adenocarcinoma of the pancreas. Patients randomised to the experimental arm will undergone tumoral biopsy before starting first line of treatment and will be administered personalised therapy as second or third line.

Phase:

Phase 2

Details

Lead Sponsor:

Centro Nacional de Investigaciones Oncologicas CARLOS III
Hospital Universitario de Fuenlabrada

Treatments:

Pancreatin
Pancrelipase